Loading…
Trial terminated
| why_stopped | null | → | The trial was intended to be Phase 1/2 but did not move forward to Phase 2 since the company providing drug and funding (Lilly) withdrew support for the trial based on data relating to abemaciclib in advanced prostate cancer. |
| overall_status | Completed | → | Terminated |
Seven dimensions, unsigned magnitude 0–100. Direction is resolved separately, per entity, because one event is good for one name and bad for another.
No other named entities identified.This event has no scored competitor read-through.
No real valuation-relevant phase transition on a resolved asset for this event.This section fires only when the event carries a resolved asset and a real phase change — not guessed for every event.